^
    Back
    Association details:
    Biomarker:ER expression
    Cancer:Endometrial Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ESMO Asia 2023
    Title:

    309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR

    Published date:
    11/27/2023
    Excerpt:
    ER expression was associated with shorter PFS of LP therapy. ER expression in tumors was a negative predictive biomarker in LP therapy for advanced endometrial cancer with pMMR.